Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$4.21B
EBITDA Margin
-250.61%
TTM Avg
-502.94%
3Y Avg
-374.26%
5Y Avg
-228.13%
Market Cap
$4.49B
EBITDA Margin
23.00%
TTM Avg
14.06%
3Y Avg
2.00%
5Y Avg
2.94%
Market Cap
$4.50B
EBITDA Margin
-31.52%
TTM Avg
-36.86%
3Y Avg
-49.55%
5Y Avg
-49.55%
Market Cap
$4.78B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$4.92B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
Market Cap
$5.02B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | $4.34B | N/A | N/A | N/A | N/A |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | -250.61% | -502.94% | -374.26% | -228.13% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.49B | 23.00% | 14.06% | 2.00% | 2.94% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.50B | -31.52% | -36.86% | -49.55% | -49.55% |
| ICU Medical, Inc. (ICUI)vs › | $4.03B | 14.57% | 8.24% | 9.01% | 11.36% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | -14.19% | -47.13% | -77.82% | -97.39% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 9.15% | -7.04% | -33.99% | -33.99% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | -70.74% | -2343.52% | -1340.84% | -951.82% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
